Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 results:
Product sales: $1,515.1M (+76.7%).
Top sellers: Trikafta: $895M; Symdeko/Symkevi: $173M (-45.9%); Orkambi: $234M (-20.1%); Kalydeco: $213M (-12.7%).
Net income: $602.8M (+124.4%); non-GAAP net income: $674.5M (+128.0%); EPS: $2.29 (+122.3%); non-GAAP EPS: $2.56 (+124.6%).
2020 guidance: Product sales: $5.3B – 5.6B from $5.1B – 5.3B.
Shares up 3% after hours.
https://seekingalpha.com/news/3566372-vertex-q1-sales-up-77-on-strong-trikafta-ramp-shares-up-3-after-hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.